Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

367 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study.
Reich K, Gooderham M, Bewley A, Green L, Soung J, Petric R, Marcsisin J, Cirulli J, Chen R, Piguet V. Reich K, et al. Among authors: piguet v. J Eur Acad Dermatol Venereol. 2018 Mar;32(3):397-402. doi: 10.1111/jdv.14738. Epub 2018 Jan 29. J Eur Acad Dermatol Venereol. 2018. PMID: 29220542 Free PMC article. Clinical Trial.
The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE).
Reich K, Gooderham M, Green L, Bewley A, Zhang Z, Khanskaya I, Day RM, Goncalves J, Shah K, Piguet V, Soung J. Reich K, et al. Among authors: piguet v. J Eur Acad Dermatol Venereol. 2017 Mar;31(3):507-517. doi: 10.1111/jdv.14015. Epub 2016 Dec 19. J Eur Acad Dermatol Venereol. 2017. PMID: 27768242 Free PMC article. Clinical Trial.
Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT).
Lebwohl M, Blauvelt A, Paul C, Sofen H, Węgłowska J, Piguet V, Burge D, Rolleri R, Drew J, Peterson L, Augustin M. Lebwohl M, et al. Among authors: piguet v. J Am Acad Dermatol. 2018 Aug;79(2):266-276.e5. doi: 10.1016/j.jaad.2018.04.013. Epub 2018 Apr 14. J Am Acad Dermatol. 2018. PMID: 29660425 Free article. Clinical Trial.
Tinea capitis in children: a systematic review of management.
Gupta AK, Mays RR, Versteeg SG, Piraccini BM, Shear NH, Piguet V, Tosti A, Friedlander SF. Gupta AK, et al. Among authors: piguet v. J Eur Acad Dermatol Venereol. 2018 Dec;32(12):2264-2274. doi: 10.1111/jdv.15088. Epub 2018 Jul 12. J Eur Acad Dermatol Venereol. 2018. PMID: 29797669
Evaluation of long-term efficacy, safety, and reasons for discontinuation of dupilumab for moderate to severe atopic dermatitis in clinical practice: A retrospective cohort study.
Jo CE, Georgakopoulos JR, Ladda M, Ighani A, Mufti A, Drucker AM, Piguet V, Yeung J. Jo CE, et al. Among authors: piguet v. J Am Acad Dermatol. 2020 Jun;82(6):1530-1532. doi: 10.1016/j.jaad.2020.02.029. Epub 2020 Feb 16. J Am Acad Dermatol. 2020. PMID: 32074486 No abstract available.
Comparative 12-week effectiveness and safety outcomes of biologic agents ustekinumab, secukinumab and ixekizumab for the treatment of plaque psoriasis: a real-world multicenter retrospective study.
Georgakopoulos JR, Lam K, Sandhu VK, Ighani A, Phung M, Piguet V, Yeung J. Georgakopoulos JR, et al. Among authors: piguet v. J Eur Acad Dermatol Venereol. 2020 Aug;34(8):e416-e418. doi: 10.1111/jdv.16366. Epub 2020 May 8. J Eur Acad Dermatol Venereol. 2020. PMID: 32176394 No abstract available.
Short-Term Evaluation of the Real-World Efficacy and Safety of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis: A Canadian Multicenter Retrospective Cohort Study [Formula: see text].
Jo CE, Georgakopoulos JR, Ladda M, Ighani A, Mufti A, Drucker AM, Piguet V, Yeung J. Jo CE, et al. Among authors: piguet v. J Cutan Med Surg. 2020 Sep/Oct;24(5):468-473. doi: 10.1177/1203475420928907. Epub 2020 May 22. J Cutan Med Surg. 2020. PMID: 32442020
367 results